Neuroprotective action of proline-rich polypeptide-1 in β-amyloid induced neurodegeneration in rats

Brain Research Bulletin

Volumn 86, Issue 3-4, 2011, Pages 262-271

  Yenkoyan, Konstantin ^a   Safaryan, Karen ^b   Chavushyan, Vergine ^c   Meliksetyan, Irina ^c   Navasardyan, Grizelda ^a   Sarkissian, John ^c   Galoyan, Armen ^d   Aghajanov, Michail ^a  

^a YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c Orbeli Institute of Physiology   (Armenia)

^d H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

Author keywords

Amyloid; Neurodegeneration; Neuroprotection; PRP 1

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN[25-35]; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; NEUROPROTECTIVE AGENT; PROLINE RICH POLYPEPTIDE 1; PROLINE RICH PROTEIN; TAURINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; BRAIN LEVEL; CELL POLARITY; CELL SWELLING; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; HIPPOCAMPUS; HISTOPATHOLOGY; MALE; NERVE CELL INHIBITION; NERVE DEGENERATION; NERVE STIMULATION; NEUROPROTECTION; NONHUMAN; POST TETANIC POTENTIATION; PRIORITY JOURNAL; RAT;

AMINO ACIDS; AMYLOID BETA-PEPTIDES; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGICAL PHENOMENA; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80053259049     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.08.003     Document Type: Article

References (42)

1. Abrahamyan S., Meliksetyan I., Sulkhanyan R., Sarkissian J., Galoyan A. Immunohistochemical study of immunophilin 1-15 fragment in intact frog brain, and in the brain and spinal cord of intact and spinal cord hemisectioned rats. Neurochem. Res. 2001, 26:1225-1230.
2. Conrad C., Galea L., Kuroda Y., McEwen B. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav. Neurosci. 1996, 110:1321-1334.
3. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
4. Fortune E., Rose G. Roles for short-term synaptic plasticity in behavior. J. Physiol. Paris 2002, 96:539-545.
5. Galoyan A. Brain Neurosecretoty Cytokines: Immune Response and Neuronal Survival 2004, Kluwer Academic/Plenum Publisher, New York, p. 188.
6. Galoyan A., Sarkissian J., Chavushyan V., Meliksetyan I., Avagyan Z., Poghosyan M., Vahradyan H., Mkrtchian H., Abrahamyan D. Neuroprotection by hypothalamic proline-rich peptide-1 in Abeta25-35 model of Alzheimer's disease. Alzheimers Dement. 2008, 4:332-344.
7. Galoyan A., Sarkissian J., Kipriyan T., Sarkissian E., Chavushyan V., Sulkhanyan R., Meliksetyan I., Abrahamyan S., Grigorian Y., Avetisyan Z., Otieva N. Protective effect of a new hypothalamic peptide against cobra venom and trauma-induced neuronal injury. Neurochem. Res. 2001, 26:1023-1038.
8. Galoyan A., Shakhlamov V., Aghajanov M., Vahradyan H. Hypothalamic proline-rich polypeptide protects brain neurons in aluminum neurotoxicosis. Neurochem. Res. 2004, 29:1349-1357.
9. Gladkevich A., Bosker F., Korf J., Yenkoyan K., Vahradyan H., Aghajanov M. Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders-therapeutic potential or a mirage?. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007, 31:1347-1355.
10. Golde T., Dickson D., Hutton M. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr. Alzheimer Res. 2006, 3:421-430.
11. Gong Y., Chang L L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10417-10422.
12. Haass C., Selkoe D. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid betapeptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
13. Holscher C., Gengler S., Gault V., Harriott P., Mallot H. Soluble beta-amyloid [25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur. J. Pharmacol. 2007, 561:85-90.
14. Holt J., Stiltner L., Wallace R., Raetz J. Clinical inquiries. Do patients at high risk of Alzheimer's disease benefit from early treatment?. J. Fam. Pract. 2009, 58:320-322.
15. Kamat C., Gadal S., Mhatre M., Williamson K., Pye Q., Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J. Alzheimers Dis. 2008, 15:473-493.
16. Khama-Murad A., Pavlinova L., Mokrushin A. Neurotropic effect of exogenous l-carnosine in cultured slices of the olfactory cortex from rat brain. Bull. Exp. Biol. Med. 2008, 146:1-3.
17. Klein W., Barlow A., Chrimy B., Edwards C., Freed R., Lamber M., Morgan T., Rozovsky I., Trommer B., Viola K., Wals P., Zhang C., Finch C., Krafft G. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1996, 95:6448-6453.
18. Lanctôt K., Herrmann N., Mazzotta P., Khan L., Ingber N. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry 2004, 49:439-453.
19. Lee Y.B., Lee K.H., Sohn H.S., Lee S.J., Cho K.H., Kang I.J., Kim D.W., Shin Y.K., Pai T., Hwang I.K., Won M.H. Effects of soy phytoestrogens on reference memory and neuronal cholinergic enzymes in ovariectomized rats. J. Med. Food 2009, 12:64-70.
20. Lin C.J., Huang H.C., Jiang Z.F. Cu (II) interaction with amyloid-beta peptide: a review of neuroactive mechanisms in AD brains. Brain Res. Bull. 2010, 82:235-242.
21. Mandelkow E.M., Stamer K., Vogel R., Thies E., Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 2003, 24:1079-1085.
22. Maurice T., Lockhart B., Su T., Privat A. Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists. Brain Res. 1996, 731:249-253.
23. Maynard C.J., Bush A.I., Masters C.L., Cappai R., Li Q.X. Metals and amyloid-beta in Alzheimer's disease. Int. J. Exp. Pathol. 2005, 86:147-159.
24. McKee A., Kosik K., Kowall N. Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol. 1991, 30:156-165.
25. 2+-dependent activity of acid phosphatase in cell structures of rat brain. Morfologia 2007, 131:77-80.
26. Mokrushin A., Khama-Murad A., Pavlinova L. Effects of long-term exposure of nerve cells to autoblood in in vitro model of hemorrhagic stroke. Bull. Exp. Biol. Med. 2008, 146:379-381.
27. Palkovits M., Brownstein M. Maps and Guide to Microdissection of the Rat Brain 1988, Appleton and Lange, p. 223.
28. Paxinos G., Watson Ch. The Rat Brain in Stereotaxic Coordinates: Compact 6th Edition 2005, Academic Press, New York, p. 400.
29. Pearson S., Reynolds G. Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathy. J. Chromatogr. 1991, 65:436-440.
30. Pike C., Burdick D., Walencewicz A., Glabe C., Cotman C. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 1996, 13:1676-1687.
31. Rowley H., Martin K., Marsden C. Determination of in vivo amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation. Neurosci. Methods 1995, 57:93-99.
32. Sipos E., Kurunczi A., Horváth A.J., Felszeghy K., Laroche S., Toldi J., Párducz A., Penke B., Penke Z. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease. Neuroscience 2007, 147:28-36.
33. Smith J., Lal V., Bowser D., Cappai R., Masters C., Ciccotosto G. Stimulus pattern dependence of the Alzheimer's disease amyloid-beta 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. Brain Res. 2009, 1269:176-184.
34. Townsend M., Shankar G., Mehta T., Walsh D., Selkoe D. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 2006, 572:477-492.
35. Vermetten E., Bremner J.D. Circuits and systems in stress: I. Preclinical studies. Depress. Anxiety 2002, 15:126-147.
36. Walf A.A., Frye C.A. The use of the elevated plus maze as an assay of anxiety related behavior in rodents. Nat. Protoc. 2007, 2:322-328.
37. Walsh D., Selkoe D. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
38. Xing G., Dong M., Li X., Zou Y., Fan L., Wang X., Cai D., Li C., Zhou L., Liu J., Niu Y. Neuroprotective effects of puerarin against beta-amyloid-induced neurotoxicity in PC12 cells via a PI3K-dependent signaling pathway. Brain Res. Bull. 2011, 85:212-218.
39. Xu J., Wu L. The decrease in the presynaptic calcium current is a major cause of short-term depression at a calyx-type synapse. Neuron 2005, 46:633-645.
40. Yenkoyan K., Safaryan K., Navasardyan G., Mkrtchyan L., Aghajanov M. Effects of beta-amyloid on behavioral and amino acids spectrum in rats' brain and their modulation by embryonic proteins. Neurochem. Int. 2009, 54:292-298.
41. Yu S., Wang M., Li X., Chen W., Chen J., Wang H., Ruan D. Influences of different developmental periods of taurine supplements on synaptic plasticity in hippocampal CA1 area of rats following prenatal and perinatal lead exposure. BMC Dev. Biol. 2007, 19:7-51.
42. Yu J.T., Wang N.D., Ma T., Jiang H., Guan J., Tan L. Roles of β-adrenergic receptors in Alzheimer's disease: implications for novel therapeutics. Brain Res. Bull. 2011, 84:111-117.